UCB Canada Inc. announced today that Health Canada has approved Cimzia(TM), the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). Cimzia(TM) can be dosed at 400 mg initially and at weeks two and four, followed by 200 mg every other week; for maintenance dosing, 400 mg every four weeks can be considered. Cimzia(TM) is available in Canada as of today.
The details can be read here.
No comments:
Post a Comment